Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bashford

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Bone Marrow Transplantation|March 22, 2005
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantationA Spencer, N Horvath, J Gibson, et al.
Bone Marrow Transplantation|March 14, 2003
Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastimL B To, J Bashford, S Durrant, et al.
Cytotherapy|May 15, 2002
Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapyH M Prince, J Bashford, D Wall, et al.
Leukemia Research|March 10, 1999
Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factorJ Morton, P Mollee, K Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-upR L Basser, L B To, J P Collins, et al.
Leukemia|August 23, 2001
Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemiaK Bradstock, J Matthews, G Young, et al.
British Journal of Haematology|October 1, 1996
High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study GroupJ Morton, K Taylor, I Bunce, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Bone Marrow Transplantation|March 22, 2005
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantationA Spencer, N Horvath, J Gibson, et al.
Bone Marrow Transplantation|March 14, 2003
Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastimL B To, J Bashford, S Durrant, et al.
Cytotherapy|May 15, 2002
Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapyH M Prince, J Bashford, D Wall, et al.
Leukemia Research|March 10, 1999
Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factorJ Morton, P Mollee, K Taylor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-upR L Basser, L B To, J P Collins, et al.
Leukemia|August 23, 2001
Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemiaK Bradstock, J Matthews, G Young, et al.
British Journal of Haematology|October 1, 1996
High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study GroupJ Morton, K Taylor, I Bunce, et al.
Pageof 5